SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors await a key decision from the EMA regarding its Alzheimer's drug, Blarcamesine, with an oral explanation scheduled. The community is actively discussing the implications of this oral explanation, analyzing potential outcomes and comparing Blarcamesine to existing treatments. Some traders express concerns about potential short attacks and are attempting to decipher the impact of an oral explanation.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending downwards as investors react to potential changes in ACA subsidies and broader sector headwinds affecting healthcare stocks. The community is actively debating the impact of these changes on Oscar Health's business model, with some seeing it as a buying opportunity due to long-term growth potential and oversold conditions, while others express concerns about profitability and ACA reliance. Traders are closely monitoring key support levels and awaiting further news on government actions regarding healthcare.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending amid discussions around its potential acquisition of Northern Data and its implications for GPU capacity and AI capabilities. Community members are weighing the potential for a short squeeze, given the high short interest and the involvement of figures like Tether and the Trump team. Some express frustration with the stock's performance and leadership, while others remain optimistic about Rumble's long-term prospects in the media and cloud space.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

GLTO is trending as traders discuss its potential for another run, fueled by a small float and high volatility. Community members are debating entry points, profit-taking strategies, and the possibility of a short squeeze. Some are comparing it to other recent high-flying stocks with similar setups.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano (MOVE) is trending due to news of Nasdaq granting an extension to regain listing compliance, sparking significant community interest and heavy trading volume. Community discussions revolve around potential price targets and whether the stock can sustain its upward momentum, with some anticipating a squeeze. The stock's low float and history of volatility are also contributing to the heightened attention.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind's stock is trending downwards following news that its Phase 3 trial for nebulized clofazimine failed to demonstrate efficacy, leading the company to discontinue the trial and shift focus to a dry powder version. The community is expressing disappointment with the company's leadership and questioning the future of the stock, with some speculating about a potential acquisition. Investors are discussing the implications for future earnings and expressing concern about the company's pipeline and strategic decisions.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

$GALT is trending due to growing excitement surrounding presentations at the AASLD Liver Meeting in November, where Belapectin's potential in treating MASH cirrhosis will be highlighted. The community is actively discussing the possibility of a buyout or partnership, particularly with companies seeking to enhance their GLP-1 portfolios, and speculating on a potential short squeeze fueled by high short interest.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is trending as investors debate the cause of recent price declines despite seemingly positive financial results, with community members pointing to competition from Roche and potential profit-taking as factors. Discussion revolves around whether the company will be acquired, if a buyback will occur, and the impact of insider share transfers. Bullish arguments center on Briumvi's market position and potential, while bears cite chart patterns and macro conditions.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following impressive Q3 results, including exceeding EPS and revenue expectations, which has sparked a surge in pre-market trading. The community is focused on the company's strong fundamentals, low float, and potential short squeeze, with many believing the stock is currently undervalued. Bullish sentiment is fueled by raised full-year guidance and comparisons to competitors, while some express concern over potential market volatility and historical price patterns.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid an escalating bidding war with Novo Nordisk to acquire Metsera, a company focused on obesity drug development, with community discussion centered on whether Pfizer is overpaying. News of Pfizer's Q3 earnings, which beat expectations but revealed weakness in key areas, is also driving conversation, with some investors expressing frustration over the stock's limited upward movement despite positive financial results. Broader market context involves potential rotation into undervalued healthcare stocks and speculation about strategic acquisitions in the obesity treatment space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The combined entity aims to compete in the high-performance cloud and GPU infrastructure market.</li><li>Upon closing, Corvex shareholders will hold roughly 96.2% of the combined company, while Movano shareholders will own about 3.8%.</li><li>The merger is expected to close in the first quarter of 2026.</li></ul>Movano Inc. (MOVE) and Corvex Inc., a U.S.-based artificial intelligence (AI) cloud infrastructure firm, announced on Monday plans to merge in an all-stock transaction that will create a new publicly traded company positioned to capitalize on the increased demand for large-scale AI computing.&nbsp;The combined entity aims to compete in the high-performance cloud and GPU infrastructure market as AI workloads surge globally.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/MOVE">Movano’s stock</a> traded over 178% higher on Monday, after the morning bell. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume jumped to 'extremely high’' from ‘low’ levels in 24 hours.<h2 class="st-heading-2">Transaction Details and Capital Structure</h2>Under the merger terms, the transaction values Movano shares at $6.25 each. Corvex and Movano have raised about $40 million in private placement financing to support the deal.&nbsp;Upon closing, Corvex shareholders will hold roughly 96.2% of the combined company, while Movano shareholders will own about 3.8%. The firms expect approximately 48.7 million shares to be outstanding following completion.<h2 class="st-heading-2">What Does Corvex Do?&nbsp;</h2>Corvex operates an AI-focused data infrastructure, offering GPU clusters, high-speed storage, and confidential computing environments designed to secure customer data while boosting model training and inference performance.&nbsp;The combined company will operate under the Corvex name and be headquartered in Arlington, Virginia, led by Corvex co-founders Seth Demsey and Jay Crystal as co-chief executive officers. The merger has been approved by the boards of both companies and is expected to close in the first quarter of 2026.MOVE stock has lost over 91% of its value year-to-date and more than 88% in the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/datavault-ai-takes-wolfpack-research-to-court-retail-traders-rally-behind-it/cLPcm0oRE2Q">Datavault AI Takes Wolfpack Research To Court: Retail Traders Rally Behind It</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

People visit the 2025 World Internet Conference (2025 WIC) Light of Internet Expo.

Movano Stock Surges 178% After Announcing Merger With AI Cloud Firm Corvex

The combined entity aims to compete in the high-performance cloud and GPU infrastructure market.

Equity

Under the merger terms, the transaction values Movano shares at $6.25 each.


CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO, CREATING A PURE-PLAY PLATFORM FOR SECURE AI INFRASTRUCTURE AND HIGH-PERFORMANCE INFERENCE

CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO, CREATING A PURE-PLAY PLATFORM FOR SECURE AI INFRASTRUCTURE AND HIGH-PERFORMANCE INFERENCE CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO...

Barclays says equities likely to keep climbing

Investing.com -- Equity markets appear poised to continue their upward trajectory, according to Barclays strategists, as falling rates volatility, solid corporate earnings, and persistent rotation into international stocks support the rally.

Movano Health Commences Clinical Study with New Cuffless Blood Pressure Device

Movano Health Commences Clinical Study with New Cuffless Blood Pressure Device Movano Health Commences Clinical Study with New Cuffless Blood Pressure Device PR Newswire PLEASANTON, Calif., Feb. 4...

Movano Health Launches EvieAI Virtual Wellness Assistant

Movano Health Launches EvieAI Virtual Wellness Assistant Movano Health Launches EvieAI Virtual Wellness Assistant PR Newswire PLEASANTON, Calif., Jan. 8, 2025 Newest Evie Ring feature is the first...

Movano Health Welcomes Dr. Shaheen Wirk to its Board of Directors

Movano Health Welcomes Dr. Shaheen Wirk to its Board of Directors Movano Health Welcomes Dr. Shaheen Wirk to its Board of Directors PR Newswire PLEASANTON, Calif., Jan. 2, 2025 PLEASANTON, Calif...

Movano Health Receives FDA Clearance for EvieMED Ring

Movano Health Receives FDA Clearance for EvieMED Ring Movano Health Receives FDA Clearance for EvieMED Ring PR Newswire PLEASANTON, Calif., Dec. 2, 2024 Company's first 510(k) clearance unlocks a TAM...

Movano Health Reports Q3 2024 Financial Results and Provides Business Update

Movano Health Reports Q3 2024 Financial Results and Provides Business Update Movano Health Reports Q3 2024 Financial Results and Provides Business Update PR Newswire PLEASANTON, Calif., Nov. 14, 2024...

Movano Health Announces Completion of Clinical Study with Cuffless RF Blood Pressure Device

Movano Health Announces Completion of Clinical Study with Cuffless RF Blood Pressure Device Movano Health Announces Completion of Clinical Study with Cuffless RF Blood Pressure Device PR Newswire...

Movano Health Provides Update on Investigation to Expose Apparent Stock Manipulation Following Reverse Stock Split

Movano Health Provides Update on Investigation to Expose Apparent Stock Manipulation Following Reverse Stock Split Movano Health Provides Update on Investigation to Expose Apparent Stock Manipulation...

$LLY

$NVO

$VKTX

$HIMS

Which obesity-drug stock are you most bullish on over the next 5 years?

MOVE
Movano Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MOVE News

MOVEMovano Inc